NUMARES
8.6.2020 14:02:12 CEST | Business Wire | Press release
numares appoints Winton Gibbons, as new president of its US subsidiary, numares Group Corp., effective of June 1st , 2020. Mr. Gibbons will further strengthen commercialization of numares’ products, and help expand the existing network of collaboration partners and investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005045/en/
Winton Gibbons brings to numares almost 30 years of experience related to life science businesses, particularly diagnostics. He has extensive experience in business development, strategy, and new product innovation, as well as in financial services and management consulting. As head of numares Group Corp., he will be responsible for further commercializing the company’s in-vitro diagnostic products, growing collaborations, and expanding investors.
“We are very excited to have Winton Gibbons joining us,” says Dr. Volker Pfahlert, Chief Executive Officer of numares . “His large pool of experiences in the IVD sector will help us unlock even more possibilities in the US market to support numares in its North American expansion. His in-depth knowledge and relevant experience in developing early- and mid-stage in-vitro diagnostic and life science firms will be invaluable to numares .”
German diagnostics company numares has its main market in the United States, providing a unique diagnostics approach – the “numares model,” a distinctive nuclear magnetic resonance (NMR) technology to identify metabolite constellations for diagnostic purposes. Just recently, numares and US-based Mayo Clinic Laboratories announced their collaboration to develop new diagnostic tests.
"I am excited to lead numares in the US. In a relatively short time, numares has built a strong track record as a provider of a unique diagnostic approach, and is now focused on some very exciting new products,” commented Mr. Gibbons. “I look forward to building the market for the company’s innovative product pipeline, some of which should be filed with the FDA by yearend.”
In recent years, Mr. Gibbons has consulted for innovative clinical diagnostic and life science companies, focusing on market assessment, business development, and strategy. Prior to that he was Senior Vice President of corporate development for Agena Bioscience, following his position as CEO and President of Siloam Biosciences, where he evaluated and implemented strategic options for the company, secured bridge financing, and managed investment banking relationships. This followed his senior management roles in business development for Nanosphere, and strategic marketing for Biosite. Leading up to this, Mr. Gibbons spent 8 years at William Blair, a global investment banking & wealth management firm, where he was a Principal, sell-side Stock Analyst, and Healthcare Equity Research Group Head. Early in his career, he was a consultant and manager for McKinsey & Company, after which he worked for Boehringer Mannheim and Merck. He has also served on several industry and academic advisory boards. Mr. Gibbons holds an MBA from the University of Chicago, and a degree in chemistry from Duke University.
About numares
numares , based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolic data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The company’s AXINON® system employs nuclear magnetic resonance (NMR) spectroscopy to create a spectrum standardized by Magnetic Group SignalingTM (MGS® ) to evaluate metabolite constellations. MGS® is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests are an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. More information: https://www.numares.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI: The New Insider Threat Facing Organizations25.2.2026 09:00:00 CET | Press release
Thales 2026 Data Threat Report Finds 70% of Organizations Rank AI as Top Data Security Risk As AI systems gain broader access to enterprise data across environments, organizations must treat data visibility and encryption as core security elements. AI-enabled deepfakes and misinformation are increasing the effectiveness of identity-based attacks. Today, credential theft is the leading attack technique against cloud infrastructure (67%). Nearly 60% of companies report deepfake-driven incidents, and 48% experience damage from AI-generated misinformation Investment in AI security is growing, with 30% of companies allocating dedicated budgets; however, 53% are still relying on existing security budget According to the Thales 2026 Data Threat Report, organizations across various markets including automotive, energy, finance and retail say the rapid pace of AI-driven transformation is now their biggest security challenge. Based on the report’s research, conducted by S&P Global 451 Research,
Zuper and Vonage Reimagine Network Connectivity for Skilled Trades with Quality on Demand25.2.2026 09:00:00 CET | Press release
Zuper to receive early access to Vonage Quality on Demand network API, for high-stakes field workflows - ensuring reliable network performance for live video, wearables, and inspections across industries like HVAC, electrical, general construction, roofing, manufacturing, and more Zuper, the AI operating system for the trades, and Vonage, part of Ericsson, have entered into a Memorandum of Understanding (MoU) to enter into a collaboration to integrate Vonage’s network APIs into the Zuper platform. The collaboration will provide Zuper with early access to Vonage network powered solutions, starting with Quality on Demand (QoD), where mobile network performance can be selectively applied to support critical field workflows, delivering improved latency, reliability, and connected experiences for mobile workforces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225852261/en/ QoD is the first advanced network API being integrat
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom